Skip to main content
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
    • English
    • Español

Breadcrumb

  1. Home
29 July 2019

ORYZON Announces End of Patient Recruitment for its Phase IIa trials in aggression with vafidemstat: REIMAGINE and REIMAGINE-AD

25 July 2019

ORYZON raises its share capital by EUR 20 Million through a private placement

16 July 2019

ORYZON presents data from ETHERAL Phase IIa trial at the 2019 Alzheimer's Association International Conference in Los Angeles

14-18 July 2019

2019 Alzheimer's Association International Conference (AAIC-2019)

Los Angeles Convention Center

CA

United States

10 July 2019

ORYZON to present data from ETHERAL Phase IIa trial at the 2019 Alzheimer's Association International Conference in Los Angeles

14 June 2019

ORYZON presents preliminary dose finding results of Phase II trial with iadademstat in AML

3 June 2019

ORYZON to present first clinical data from ALICE Phase IIa trial with iadademstat at the 24th Congress of the European Hematology Association

29 May 2019

ORYZON announces First Patient in the US in ETHERAL-US: a Phase IIa clinical trial with vafidemstat in Alzheimer’s Disease

20 May 2019

ORYZON Receives $1.5 million grant from Alzheimer’s Drug Discovery Foundation (ADDF)

13 May 2019

ORYZON Reports Financial Results and Corporate Update for the 1st Quarter, 2019

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • Current page 34
  • Page 35
  • Page 36
  • Page 37
  • Page 38
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel

We use our own and third-party cookies for analytical purposes. You can obtain more information in our Cookies Policy. Likewise, you can accept all our own and third-party cookies that we use by pressing the “Accept Cookies” button, reject all cookies by pressing the “Reject Cookies” button or access the configuration panel by pressing the “Configure” button.

Privacy Summary

This Website uses cookies that store and retrieve information when you are browsing. In general, these technologies can serve very different purposes, such as recognizing you as a user, obtaining information about your browsing habits or personalizing the way in which content is displayed. Click the headers for each cookie type to change our default settings:

These are those that allow the user to navigate through a website, platform or application and the use of the different options or services that exist in it. These cookies do not store any personal information.
Analytical cookies are used to understand how visitors interact with the website. These cookies help to provide information about metrics, number of visitors, bounce rate, traffic source, etc.
Back to top